1 High-Flying Stock to Buy Hand Over Fist if the Stock Market Crashes

Nov 20, 2026
1-high-flying-stock-to-buy-hand-over-fist-if-the-stock-market-crashes

Prosper Junior Bakiny, The Motley Fool

5 min read

Innovation often pays off. Moderna (NASDAQ:MRNA) has proven as much this year. The company’s shares have soared in 2026 on the back of impressive clinical and regulatory progress. But is there any upside left for the vaccine maker? Not in my view. But Moderna would be a great stock to buy if the stock market crashes. Read on to find out more.

Red Moderna sign with blue accents on a modern building exterior

Image source: Getty Images.

Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a “Double Down” signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same “Total Conviction” signal is flashing for a company 1/100th the size of Nvidia. Continue »

Moderna’s impressive accomplishment

Moderna is pioneering mRNA-based personalized cancer vaccines. These products offer the potential to train patients’ immune systems to recognize and destroy cancer cells based on specific mutations present in each patient’s tumor. This approach could lead to much greater treatment efficacy than conventional cancer medicines. Personalized cancer vaccines may also more effectively prevent recurrence.

Moderna provided the first positive Phase 3 clinical trial data for an investigational personalized cancer vaccine, intismeran autogene, earlier this year. Moderna is developing intismeran autogene with Merck (NYSE:MRK), and in this Phase 3 study, the personalized cancer vaccine was tested as a combination therapy with Keytruda — the best-selling cancer drug in the world — versus Keytruda alone in certain patients with melanoma. Intismeran autogene, combined with Keytruda, led to meaningful improvements in recurrence-free survival. This clinical win sent Moderna’s shares up by more than 100% overnight.

The price is not right

The market is seeing beyond Moderna’s clinical win. The company proved that personalized cancer vaccines can reach significant clinical success. Intismeran autogene hasn’t done so yet, but based on its Phase 3 results, it should eventually generate significant sales. Some analysts expect the personalized cancer vaccine to generate more than $10 billion in revenue at its peak, especially as it earns approvals across additional indications beyond melanoma.

It is being invested in as a treatment across several other forms of cancer. And the rest of the company’s lineup and pipeline also looks robust. For instance, Moderna has earned approval for mFLUSIVA, an influenza vaccine, earlier this year. Its coronavirus vaccine is still on the market, and it is developing several other candidates in infectious diseases.

Leave a comment